Covid-19 Innovation Challenges by Innoget

New use for an existing drug as antiviral agent against SARS-CoV-2 to prevent or/and treat COVID-19

Posted by Covid-19 Innovation Challenges by InnogetVery responsive · Patents for licensing · United Kingdom

Summary of the technology

CSIC has discovered a new use for an existing drug on the market as antiviral agent.
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Covid-19 Innovation Challenges by Innoget

Description of the technology

These days there is a need for safe and effective antiviral agents with a wide spectrum of anti-viral activity. Since the emergence of a novel coronavirus (SARS-CoV-2) from Wuhan, China, in December 2019, that has caused millions of cases of human infections and huge cases of deaths globally and was declared as a pandemic by World Health Organisation, broad-spectrum antivirals for the treatment of emerging and endemic CoVs are needed.

The virus spreads rapidly from the transmission among human, and the symptoms caused by the virus (abbreviated “COVID-19”) ranges from mild cough and fever to severe pneumonia and potentially life-threatening symptoms. Waiting for the availability of new vaccines, this global emergency has triggered the search for safe and effective pharmacological approaches for eradicating the virus, or at least reducing its effects and hindering the contagion, since, currently there is only one approved therapy to treat SARS-CoV-2 infection. By using a computational approach, the library of FDA approved drugs, already used in humans, has been screened to identify in a quick and efficient way potential antiviral agents against SARS-CoV-2 to be subsequently studied in the corresponding biological studies. In this way, a promising candidate has been found.

Intellectual property status

Patent already applied for

Patent application number : EP20382736.5

Where : Spanish Patent and Trademark Office (www.oepm.es)

Technology Owner

Covid-19 Innovation Challenges by Innoget

Innovation Intermediary

Additional information (attached documents)

Related keywords

  • Applications for Health
  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Pharmaceutical Products / Drugs
  • Virus, Virology / Antibiotics / Bacteriology
  • Human vaccines
  • Biology / Biotechnology
  • Protecting Man and Environment
  • Infectious Diseases
  • Medical/health
  • Other Medical/Health Related
  • Consumer related
  • Industrial Products
  • Covid-19
  • antiviral
  • sars-cov-2

About Covid-19 Innovation Challenges by Innoget

Innovation Intermediary from United Kingdom

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.